Current Status and Future Perspectives on Machine Perfusion: A Treatment Platform to Restore and Regenerate Injured Lungs Using Cell and Cytokine Adsorption Therapy : A Treatment Platform to Restore and Regenerate Injured Lungs Using Cell and Cytokine Adsorption Therapy
(2022) In Cells 11(1).- Abstract
- Since its advent in the 1990′s, ex vivo lung perfusion (EVLP) has been studied and implemented as a tool to evaluate the quality of a donor organ prior to transplantation. It provides an invaluable window of opportunity for therapeutic intervention to render marginal lungs viable for transplantation. This ultimately aligns with the need of the lung transplant field to increase the number of available donor organs given critical shortages. As transplantation is the only option for patients with end-stage lung disease, advancements in technology are needed to decrease wait-list time and mortality. This review summarizes the results from the application of EVLP as a therapeutic intervention and focuses on the use of the platform with regard... (More)
- Since its advent in the 1990′s, ex vivo lung perfusion (EVLP) has been studied and implemented as a tool to evaluate the quality of a donor organ prior to transplantation. It provides an invaluable window of opportunity for therapeutic intervention to render marginal lungs viable for transplantation. This ultimately aligns with the need of the lung transplant field to increase the number of available donor organs given critical shortages. As transplantation is the only option for patients with end-stage lung disease, advancements in technology are needed to decrease wait-list time and mortality. This review summarizes the results from the application of EVLP as a therapeutic intervention and focuses on the use of the platform with regard to cell therapies, cell product therapies, and cytokine filtration among other technologies. This review will summarize both the clinical and translational science being conducted in these aspects and will highlight the opportunities for EVLP to be developed as a powerful tool to increase the donor lung supply. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/6d3ca733-18c2-4a8d-a41d-e136fcc7d2a3
- author
- Niroomand, Anna LU ; Hirdman, Gabriel LU ; Olm, Franziska LU and Lindstedt, Sandra LU
- organization
-
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Thoracic Surgery
- WCMM-Wallenberg Centre for Molecular Medicine
- Acoustofluidics group (research group)
- Clinical and experimental lung transplantation (research group)
- Lung Bioengineering and Regeneration (research group)
- NPWT technology (research group)
- DCD transplantation of lungs (research group)
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cells
- volume
- 11
- issue
- 1
- article number
- 91
- publisher
- MDPI AG
- external identifiers
-
- scopus:85121775947
- pmid:35011653
- ISSN
- 2073-4409
- DOI
- 10.3390/cells11010091
- language
- English
- LU publication?
- yes
- id
- 6d3ca733-18c2-4a8d-a41d-e136fcc7d2a3
- date added to LUP
- 2022-01-04 09:32:52
- date last changed
- 2024-11-03 14:08:06
@article{6d3ca733-18c2-4a8d-a41d-e136fcc7d2a3, abstract = {{Since its advent in the 1990′s, ex vivo lung perfusion (EVLP) has been studied and implemented as a tool to evaluate the quality of a donor organ prior to transplantation. It provides an invaluable window of opportunity for therapeutic intervention to render marginal lungs viable for transplantation. This ultimately aligns with the need of the lung transplant field to increase the number of available donor organs given critical shortages. As transplantation is the only option for patients with end-stage lung disease, advancements in technology are needed to decrease wait-list time and mortality. This review summarizes the results from the application of EVLP as a therapeutic intervention and focuses on the use of the platform with regard to cell therapies, cell product therapies, and cytokine filtration among other technologies. This review will summarize both the clinical and translational science being conducted in these aspects and will highlight the opportunities for EVLP to be developed as a powerful tool to increase the donor lung supply.}}, author = {{Niroomand, Anna and Hirdman, Gabriel and Olm, Franziska and Lindstedt, Sandra}}, issn = {{2073-4409}}, language = {{eng}}, number = {{1}}, publisher = {{MDPI AG}}, series = {{Cells}}, title = {{Current Status and Future Perspectives on Machine Perfusion: A Treatment Platform to Restore and Regenerate Injured Lungs Using Cell and Cytokine Adsorption Therapy : A Treatment Platform to Restore and Regenerate Injured Lungs Using Cell and Cytokine Adsorption Therapy}}, url = {{http://dx.doi.org/10.3390/cells11010091}}, doi = {{10.3390/cells11010091}}, volume = {{11}}, year = {{2022}}, }